- 1 Antibody responses to a suite of novel serological markers for malaria surveillance demonstrate
- 2 strong correlation with clinical and parasitological infection across seasons and transmission
- 3 settings in The Gambia
- 5 Author details

- 6 Lindsey Wu^{1*}, Julia Mwesigwa², Muna Affara³, Mamadou Bah², Simon Correa², Tom Hall⁴, James
- 7 Beeson⁵, Kevin K.A. Tetteh¹, Immo Kleinschmidt^{6,7}, Umberto D'Alessandro², Chris Drakeley¹
- ***Corresponding author:** lindsey.wu@lshtm.ac.uk
- 9 1. London School of Hygiene and Tropical Medicine (LSHTM), Faculty of Infectious Tropical Diseases,
- 10 Department of Infection Biology. London WC1E 7HT, UK.
- 11 2. Medical Research Council Unit The Gambia at London School of Hygiene and Tropical Medicine.
- 12 Fajara, The Gambia.
- 13 3. Bernhard Nocht Institute for Tropical Medicine (BNITM). Arusha, Tanzania.
- 4. St. George's University of London (SGUL). London, United Kingdom.
- 15 5. Burnet Institute. Melbourne, Australia.
- 16 6. London School of Hygiene and Tropical Medicine (LSHTM), Faculty of Epidemiology and Population
- 17 Health, Department of Infectious Disease Epidemiology. London WC1E 7HT, UK.
- 18 7. School of Pathology, Wits Institute for Malaria Research, Faculty of Health Science, University of
- 19 Witwatersrand, South Africa.
- 21 Email addresses:

20

- 22 LW: lindsey.wu@lshtm.ac.uk
- 23 JM: julia.mwesigwa@lshtm.ac.uk
- 24 MA: affara@bnitm.de

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 MB: mmbah@mrc.gm 26 SC: scorea@mrc.gm TH: thall@sgul.ac.uk 27 28 JB: beeson@burnet.edu.au 29 KKAT: kevin.tetteh@lshtm.ac.uk IK: immo.kleinschmidt@lshtm.ac.uk 30 31 UD: umberto.dalessandro@lshtm.ac.uk 32 CD: chris.drakeley@lshtm.ac.uk 33 Keywords: malaria, serology, surveillance 34 35 36 Abstract 37 **Background** 38 As malaria transmission declines, sensitive diagnostics are needed to evaluate interventions and 39 monitor transmission. Serological assays measuring malaria antibody responses offer a cost-effective 40 detection method to supplement existing surveillance tools. 41 Methods 42 A prospective cohort study was conducted from 2013 to 2015 in 12 villages across five administrative 43 regions in The Gambia. Serological analysis included samples from the West Coast Region at the start and end of the season (July and December 2013) and from the Upper River Region in July and 44 December 2013, and April and December 2014. Antigen-specific antibody responses to seven 45 Plasmodium falciparum (P.falciparum) antigens - Etramp5.Ag1, GEXP18, HSP40.Ag1, Rh2.2030, 46 47 EBA175 RIII-V, PfMSP1₁₉, PfAMA1 - were quantified using a multiplexed bead-based assay. The 48 association between antibody responses and clinical and parasitological endpoints was estimated at 49 the individual, household, and population level.

Results

Strong associations were observed between clinical malaria and concurrent sero-positivity to Etramp5.Ag1 (aOR 4.56 95%CI 2.94 – 7.06), *Pf*MSP1₁₉ (aOR 3.84 95%CI 2.41 – 6.04) and *Pf*AMA1 (aOR 2.18 95%CI 1.23 – 3.84), while asymptomatic infection was associated with sero-positivity to all antigens. Village-level sero-prevalence amongst children 2-10 years against Etramp5.Ag1, HSP40.Ag1, and *Pf*MSP1₁₉ showed the highest correlations with clinical and *P.falciparum* infection incidence rates. For all antigens, there was increased odds of asymptomatic *P.falciparum* infection in subjects residing in a compound with greater than 50% sero-prevalence, with a 2- to 3-fold increase in odds of infection associated with Etramp5.Ag1, GEXP18, Rh2.2030, *Pf*MSP1₁₉ and *Pf*AMA1. For individuals residing in sero-positive compounds, the odds of clinical malaria were reduced, suggesting a protective effect.

Conclusions

At low transmission, long-lived antibody responses could indicate foci of malaria transmission that have been ongoing for several seasons or years. In settings where sub-patent infections are prevalent and fluctuate below the detection limit of polymerase chain reaction (PCR), the presence of short-lived antibodies may indicate recent infectivity, particularly in the dry season when clinical cases are rare. Serological responses may reflect a persistent reservoir of infection, warranting community-targeted interventions if individuals are not clinically apparent but have the potential to transmit. Therefore, serological surveillance at both the individual and household level may be used to target interventions where there are foci of asymptomatically infected individuals.

Background

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

As malaria transmission declines, the prevalence of infection becomes increasingly heterogeneous and focal. In low transmission settings, highly sensitive diagnostics are needed to measure subtle changes in malaria incidence, evaluate the effectiveness of community-based interventions, and monitor potential re-introduction after elimination. Evidence suggests that infections below the detection limit of microscopy and rapid diagnostic tests (RDTs) contribute to on-going transmission, but the magnitude of their public health importance is yet to be determined.¹⁻³ Nucleic acid amplification tests (NAATs), such as ultrasensitive quantitative polymerase chain reaction (qPCR), can detect less than 1 parasite per microlitre^{4,5}, but are still sensitive to fluctuations in parasite density during the course of an infection. Serological assays measuring antibody responses may be a more stable diagnostic alternative, offering a cost-effective detection method to supplement existing surveillance tools. A number of studies in The Gambia have observed spatiotemporal variations in antibody responses to malaria over time^{6,7}, with similar observations in Tanzania⁸, Equatorial Guinea⁹, and South Africa¹⁰. Newly developed serological markers of recent exposure to malaria may now be capable of measuring short-term changes in malaria transmission over periods as short as 1-2 years. However, these markers require validation with population-representative data from a range of endemic settings^{11,12}. Longitudinal cohort studies provide a unique opportunity for a multi-metric assessment of transmission dynamics using clinical, parasitological, and serological endpoints. The aim is to understand the relative accuracy of different diagnostics and their utility in epidemiological surveillance. Using a suite of novel serological markers of malaria exposure, this study determines the correlation of antibody responses with clinical and parasitological endpoints at the individual, household, and population level in four villages in rural Gambia over two years, estimating the strength of association between serological markers and gold standard metrics of malaria infection. These findings will support the utility of serology in measuring recent malaria transmission and allow selection of markers most suitable for use in future surveillance, particularly for reactive detection strategies in elimination settings.

Methods

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

Data and sampling

A prospective cohort study was conducted from 2013 to 2015 in 12 villages across five administrative regions - West Coast (WCR), North Bank (NBR), Lower River (LRR), Central River (CRR) and Upper River (URR) Regions. Plasmodium falciparum (Pf) prevalence measured by polymerase chain reaction (PCR) ranged from 2.27 to 19.60% in the Central River and Upper River Regions respectively (Figure 1). As described by Mwesigwa et al,13 the study aim was to understand the dynamics of malaria infection and the impact of annual mass drug administration (MDA). Residents more than six months of age were enrolled in the study, and monthly surveys were conducted during malaria transmission season from June to December each year, as well as surveys in the dry season in April 2014, and prior to the implementation of MDA in May and June 2014 and 2015. Individual finger prick blood samples were collected for haemoglobin estimation and on filter paper (Whatman 3 Corporation, Florham Park, NJ, USA) for molecular and serological analysis. Clinical malaria cases were identified by passive case detection (PCD) at health facilities or in villages by study nurses in individuals with history of fever in the previous 24 hours or axillary temperature ≥ 37.5°C and a positive Rapid Diagnostic Test (RDT) result (Paracheck Pf, Orchid Biomedical System, India). Serological analysis included all available samples from the West Coast Region in Besse and N'Demban villages from surveys conducted at the start of the transmission season in July 2013 (N=537) and at the end of the season in December 2013 (N=526). In the Upper River Region, analysis included all samples collected in Njaiyal and Madino Samako in July 2013 (N=779), December 2013 (N=632), April (dry season) 2014 (N=823), and December 2014 (N=757) (Figure 1, Table 1). These regions represent extremes of two transmission intensities, with months selected at the start and end of the

transmission season. Samples from clinical PCD cases were linked by study participant identification code to samples from the same individuals collected during routine monthly surveys.

This study was approved by the Gambia Government/MRC Joint Ethics Committee (SCC1318). Verbal consent was first obtained at village sensitisation meetings, followed by individual written informed consent for all participants. Parents/guardians provided written consent for children less than 17 years, and assent was obtained from children between 12 and 17 years.

Laboratory procedures

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

Antigen-specific antibody responses were quantified using the Luminex MAGPIX protocol described in Wu et al 2019. 4 Plasma was eluted from 6mm dried blood spots (DBS) (4 μl whole blood equivalent) and shaken overnight at room temperature in 200 µl of protein elution buffer containing phosphate buffered saline (PBS) (pH 7.2), 0.05% sodium azide and 0.05% Tween-20, yielding an initial 1:50 sample dilution. One day prior to assay processing, samples were diluted to a final 1:500 dilution using 10 µl of the 1:50 pre-dilution sample and 90 µl of blocking Buffer B to prevent non-specific binding (1xPBS, 0.05% Tween, 0.5% bovine serum albumin (BSA), 0.02% sodium azide, 0.1% casein, 0.5% polyvinyl alcohol (PVA), 0.5% polyvinyl pyrrolidone (PVP) and 1,500 μg/ml *E.coli* extract). Negative and positive controls were also incubated one day prior in Buffer B, with negative controls prepared at a 1:500 dilution and Gambian pooled positive controls in a 6-point 5-fold serial dilution (1:10-1:31,250). The positive control was based on a pool of 22 serum samples from malaria hyper-immune individuals in The Gambia, and ten individual plasma samples from European malaria-naive adults were used as negative controls. Samples were prepared for diagnostic PCR as described by Mwesigwa et al 2017.¹³ Briefly, DNA was extracted from three 6-mm DBS using the automated QIAxtractor robot (Qiagen). Negative and positive (3D7) controls were included to control for cross contamination and DNA extraction efficiency, respectively. The DBS were lysed by incubation in tissue digest buffer at 60 °C for 1 hour and digested eluates were applied onto capture plates, washed, and the DNA eluted into 80 µl. The

extracted DNA (4 µl) was used in a nested PCR, amplifying the multi-copy *Plasmodium* ribosomal RNA gene sequences using genus and species specific primers.¹⁵ All PCR products were run using the QIAxcel capillary electrophoresis system (Qiagen), using the screening cartridge and 15-1,000 bp-alignment marker. Results were exported and double scored using both the QIAxcel binary scoring function and manually by visualization of the gel images and discrepancies were scored by a third independent reader. All readers were blinded to participant survey data.

Statistical analyses

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

Data analysis was based on total immunoglobulin (IgG) levels to five antigens as potential markers of sero-incidence¹⁶ - early transcribed membrane protein 5 (Etramp5.Ag1), gametocyte export protein 18 (GEXP18), heat shock protein 40 (HSP40.Ag1), erythrocyte binding antigen 175 RIII-V (EBA175), reticulocyte binding protein homologue 2 (Rh2.2030). Two antigens associated with long-lived antibody response - P.falciparum merozoite surface antigen 1 19-kDa carboxy-terminal region (PfMSP1₁₉) and P.falciparum apical membrane antigen 1 (PfAMA1) – were included as a comparison, both historically used to assess sero-conversion rates over time^{8,9} and previously studied in The Gambia^{6,7}. For antigens associated with long-lived antibodies (PfMSP1₁₉, PfAMA1), a two-component Gaussian mixture model was used to define distributions of negative and positive antibody levels, expressed in units of median fluorescence intensity (MFI). Sero-positivity thresholds were defined as the mean log MFI values plus two standards deviations of the negative distribution.¹⁷ Mixture models were estimated using the 'normalmixEM' function in the 'mixtools' package v1.0.4 in R version 3.6.1. For antigens associated with shorter-lived antibodies where statistical evidence of a bimodal distribution of antibody responses in the population was not strong - Etramp5.Ag1, GEXP18, HSP40.Ag1, EBA175, Rh2.2030 - the sero-positivity threshold was defined by the mean log MFI plus three standard deviations of 71 malaria-naïve European blood donors used as negative controls. Individual-level association between antibody response and the concurrent odds of clinical malaria (passively detected via the health facility or study nurses in the community) or asymptomatic P.falciparum infection (actively detected using PCR from monthly survey samples) were assessed using generalised estimating equations (GEE). Analysis was adjusted for age group (1-5 years, 6-15 years, and greater than 15 years) and use of long-lasting insecticide treated nets (LLINs) in the last 24 hours and allowed for clustering at the compound level, where compound is a collection of households centrally located around a main residence. The magnitude of the association between antibody response and odds of infection was evaluated for interaction with age group. Using a GEE model, individual-level odds of clinical malaria or asymptomatic infection was assessed for association with residence in the same compound as a sero-positive individual. Similarly, the association between individual odds of infection and compound-level sero-prevalence (<50% or >50%), was assessed using a mixed-effects generalised linear model adjusted for age group and LLIN use, with random-effects at the compound-level. To ensure that estimates are not biased by the seroprevalence of small compounds, analysis was weighted by the number of individuals in the compound (whose sero-status was assessed) and only included compounds with at least four individuals. Models were fit using the 'geeM' and 'lme4' packages in R version 3.14. Village-level sero-prevalence in July and December 2013 amongst children aged 2-10 years was compared against all-age clinical and P.falciparum infection incidence rates from the same months, the latter of which were previously reported by Mwesigwa et al¹³. Monthly clinical and *P.falciparum* infection incidence rates were defined respectively as the number of new clinical cases or *P.falciparum* infections (PCR-positive individuals who were PCR-negative in the previous monthly survey) divided by total person-years at risk. This age range was selected to align with other routine surveillance metrics such as annual parasite index (API) commonly using this age group as a sentinel population. The strength of the relationship between village-level incidence rates and sero-prevalence for each antigen was assessed using Pearson's correlation coefficient.

Results

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

Village-level seroprevalence

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

Data from 2,005 individuals were available for analysis of antibody responses from 5,581 samples between June 2013 and December 2014 (Tables 1 and 2). The majority of subjects were female in both the West Coast (55.0%) and the Upper River (54.3%) Regions, and higher LLIN use in the West Coast (96.6%) compared to the Upper River Region (46.6%). In the West Coast Region, incidence of P. falciparum was three times higher in December than at the start of the transmission season, and five times higher in December in the Upper River Region (Table 3). Sero-prevalence amongst 2-10 years olds in the West Coast Region ranged from 1.4% (95%CI 0.0 - 3.1) for Rh2.2030 in July 2013 (start of the transmission season) and 13.7% (95%CI 8.9-18.5) for Etramp5.Ag1 in December 2013 (end of transmission season). In the Upper River Region, sero-prevalence across all antigens was higher, ranging from 5.1% (95%CI 2.5-7.7) for PfMSP1₁₉ in July to 36.1% (95%CI 30.0-42.2) for GEXP18 in December (Table 3). Sero-prevalence in this age group was highly correlated with both clinical malaria and *P.falciparum* infection incidence rates (Figure 2, Table 4). In both regions in July and December 2013, correlations between P.falciparum infection rate and seroprevalence were strongest for Etramp5.Ag1 (p=0.98), HSP40.Ag1 (p=0.99), and $PfMSP1_{19}$ (p=0.99). Incidence of clinical malaria had the strongest correlations with Etramp5.Ag1 (ρ=0.98), HSP40.Ag1 (ρ =0.95), and $PfMSP1_{19}$ (ρ =0.97). Correlations with both clinical incidence and P.falciparum infection rates remained high for Etramp5.Ag1 (ρ =0.98 and ρ =0.96, respectively) and PfMSP1₁₉ (ρ =0.96 and p=0.98, respectively), but slightly lower for HSP40.Ag1 (p=0.85 and p=0.81, for clinical incidence and P.falciparum infection rates respectively), after excluding data from December 2013 from the Upper River Region as a potential outlier. These correlations are based on few datapoints, with three observations when excluding URR December 2013. Individual-level association between clinical malaria, asymptomatic P.falciparum infection and concurrent sero-positivity The odds of clinical malaria were higher in individuals sero-positive to five (out of seven) of the antigens analysed (Etramp5.Ag1, GEXP18, Rh2.2030, PfMSP119 and PfAMA1) (Figure 3A, Table 5). After adjusting for age and LLIN use, clinical malaria was associated with concurrent sero-positivity to three antigens (Etramp5.Ag1, PfMSP1₁₉and PfAMA1), while odds of asymptomatic infection were strongly associated with sero-positivity to all antigens. Amongst individuals sero-positive for Etramp5.Ag1, there was increased odds of both clinical malaria (aOR 4.56, 95%CI 2.94 – 7.06, p<0.001) and asymptomatic infection (aOR 3.36, 95%CI 2.75 – 4.11, p<0.001) (Table 5). Association with clinical malaria was slightly lower in individuals sero-positive for PfMSP1₁₉ (aOR 3.82, 95%CI 2.41 - 6.04, p<0.001) and PfAMA1 (aOR 2.18, 95%CI 1.23 - 3.84, p=0.007). Odds of asymptomatic infection in individuals sero-positive to GEXP18 (aOR 3.10, 95%CI 2.50 – 3.85, p<0.001), Rh2.2030 (aOR 3.10, 95%CI 2.44 - 3.94, p<0.001) and PfAMA1 (aOR 3.83, 95%CI 2.95 - 4.98, p<0.001) was similar to Etramp5.Ag1.

Individual-level odds of clinical malaria, asymptomatic infection when residing in compounds with

sero-positive individuals

The odds of clinical malaria were reduced for individuals residing in the same compound with an individual sero-positive to any of the seven antigens (Figure 3B, Table 6), from an 83% reduction if residing in the same compound as an individual sero-positive for Etramp5.Ag1 (aOR 0.17, 95%Cl 0.03-0.84, p=0.03) to a 95% reduction if residing in the same compound as someone sero-positive for *Pf*AMA1 (aOR 0.05, 95%Cl 0.01 - 0.47, p=0.009). Conversely, the odds of asymptomatic infection were positively associated with residing in the same compound as sero-positive individuals for five antigens (Etramp5.Ag1, GEXP18, Rh2.2030, *Pf*MSP1₁₉, and *Pf*AMA1). Adjusted odds of asymptomatic infection was nearly 3-fold higher if residing with an individual sero-positive for Etramp5.Ag1 (aOR 2.95, 95%Cl 1.66 - 5.24, p<0.001) and for GEXP18 (aOR 2.71, 95%Cl 1.58 - 4.63, p<0.001). If residing in a compound with individuals sero-positive to Rh2.2030, *Pf*MSP1₁₉ or *Pf*AMA1, the odds of asymptomatic infection were all nearly twice as high as individuals living in compounds sero-negative to these antigens (Table 6).

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

Association between individual-level clinical malaria, asymptomatic infection, and compound seroprevalence When stratifying by compound-level sero-prevalence, mean regression estimates found a reduced odds of clinical malaria if residing in compound with sero-prevalence less than 50% for all antigens, and an increased odds of clinical malaria in compounds with greater than 50% sero-prevalence for four antigens (Etramp5.Ag1, GEXP18, HSP40.Ag1, and PfMSP119) (Figure 4A, Supplementary File 2 -Tables S3, S7, S11, S19, and S23). However, these results were not statistically significant. There was strong statistical evidence for increasing odds of asymptomatic infection with increasing compound sero-prevalence for two antigens (Etramp5.Ag1 and PfMSP119) (Figure 4B, Supplementary File 2 -Tables S4, S24), and weaker statistical evidence for increasing odds of asymptomatic infection for HSP40.Ag1 and Rh2.2030 (Supplementary File 2 - Tables S14, S16). Antigens most associated with increased odds of asymptomatic infection were Etramp5.Ag1, GEXP18 and PfMSP1₁₉. For Etramp5.Ag1, aOR 2.61 (95%CI 1.53 - 4.45, p<0.001) in compounds with less than 50% sero-prevalence to an aOR 8.32 (95%CI 5.32 - 13.03, p<0.001) in compound sero-prevalence greater than 50%, compared to sero-negative compounds (Supplementary File 2 - Table S4). For GEXP18, aOR ranged from 2.97 (95%CI 1.47 - 5.99, p=0.002) to 8.80 (95%CI 3.50 - 22.12, p<0.001) (Supplementary File 3 - Table S8). For PfMSP1₁₉, aOR ranged from 2.18 (95%CI 1.33 - 3.60, p=0.002) to aOR 9.06 (95%CI 5.16 - 15.89, p<0.001) (Supplementary File 2 - Table S24). For HSP40.Ag1, EBA175, and PfAMA1, statistically strong evidence for increased odds of asymptomatic infection was only observed in compounds with greater than 50% sero-prevalence (Supplementary File 2 - Tables S12, S20, S28). The spatial distribution of infections at both the start and end of the transmission season (June – July 2013 vs August-December 2013) suggest that clinical and asymptomatic malaria are localised near households with Etramp5.Ag1 sero-positive individuals (Figure 5). There are a number of Etramp5.Ag1

sero-positive households at both the start and during the wet season without concurrent clinical or

asymptomatic infections present. However, this is more pronounced for *Pf*AMA1, where sero-positivity could reflect a longer history of exposure than Etramp5.Ag1 (Supplementary File 3 - Figure S2). While there are a limited number of clinical cases between June and July 2013, from August to December 2013, these cases occur in proximity to households with asymptomatic and Etramp5.Ag1 sero-positive individuals.

Discussion

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

We investigated the association between antibody responses and clinical and parasitological endpoints at the individual, compound, and population level in The Gambia. At the individual level, clinical malaria was highly correlated with concurrent sero-positivity to Etramp5.Ag1, PfMSP119 and PfAMA1, while asymptomatic infection was correlated with sero-positivity to all antigens included in this study. The strongest associations were with sero-positivity to Etramp5.Ag1 and PfAMA1. Villagelevel sero-prevalence amongst children 2-10 years against antigens Etramp5.Ag1, HSP40.Ag1, and PfMSP1₁₉ showed the highest correlations with clinical incidence and Pf infection rates. At the compound level, individuals had increased odds of asymptomatic infection when residing in a compound with greater than 50% sero-prevalence to all antigens, with the highest odds associated with sero-prevalence to Etramp5.Ag1, GEXP18, and PfMSP1₁₉. These results do not imply a causal relationship between serological responses and clinical outcomes or asymptomatic infection, but highlight that infected individuals tend to be concurrently sero-positive to most of the serological markers assessed. There was strong evidence of reduced odds of clinical malaria for individuals residing in the same compound as an individual sero-positive to any of the antigens, suggesting a protective effect. While PfMSP1₁₉ and PfAMA1 have been used extensively to measure medium and long-term trends in transmission intensity, these markers may be less sensitive to changes in transmission at higher endemicities or to smaller short-term fluctuations due to the rapid acquisition of antibodies and the long half-life of sero-positivity for many blood-stage antigens. 18-21 Individuals with clinical malaria or

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

with long-lived antibody responses in low transmission regions of western Gambia could indicate foci of malaria transmission that have been ongoing for several transmission seasons or years. In areas where parasite density is low and often missed by RDTs and microscopy, using serological markers could support targeted interventions to clear or eliminate these residual reservoirs of human infection. Antigens in this study associated with shorter-lived sero-positivity (Etramp5.Ag1, GEXP18, and HSP40.Ag1) were positively correlated with either clinical malaria and asymptomatic infection, and sometimes both. These antigens have been relatively recently identified and shown to decrease rapidly after infection in Ugandan children. 16 In settings where most infections are sub-patent and fluctuate above or below the detection limit of PCR, detecting the short-lived antibody response in individuals or households could imply recent infectivity, particularly in the dry season where clinical cases are rare. While factors such as the method for determining sero-positivity cut-off values could affect estimates of sero-prevalence or the magnitude of association between endpoints, 22 the observations in this study have important implications. In particular, there is a very consistent trend of compound seropositivity being a risk factor for asymptomatic infection in contrast to being protective against clinical malaria. The complex dynamics between clinical and parasitic immunity are not explained through epidemiological data alone as previous studies have observed lower PCR density in areas of higher transmission intensity³¹. Fluctuations in sero-positivity levels may be a strong indicator of a persistent human reservoir of infection, warranting community-targeted interventions if individuals remain infected but are not clinically apparent and continue to transmit. Household serological status could be used for targeting interventions where there are foci of asymptomatically infected individuals. Immuno-epidemiological studies will be subject to variations in antigen-specific antibody dynamics, as well as the immunogenicity of recombinant antigen constructs. Differences in sequence selection and expression systems may result in recombinant proteins that differ slightly from natural epitope morphology. It is unclear the degree to which these subtle variations affect the strength of antibody detection between recombinant antigens. While this study focuses primarily on total IgG responses,

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

quantification of antibody levels using a combination of isotypes or subclasses may allow for improved detection of sero-incidence. For example, IgG3 antibodies are thought to be thought to bind more weakly than IgG1 and IgG3.²³ Current evidence on the associations of antigen-specific IgG subclasses with both exposure and immunity to malaria is varied^{24,25}. Antigens will fall along a continuum of suitability as either biomarkers of acute infection to correlates of protective immunity²⁶, and these subtleties need to be considered when selecting targets for surveillance. The assays used in this study have allowed us to quantify antibody responses to specific antigens. Therefore, it will also be valuable to investigate the optimal combinations of antigens associated with both short-lived and long-lived antibody responses in surveillance, which could be more routinely used to account for the breadth of antibody response between individuals in a population.^{27–29} Variations such as this could also potentially be overcome by the use of multiple variants or chimeric antigen constructs.³⁰ Changing household sero-prevalence throughout the season may influence the precision of estimates, which could be overcome with more frequent sampling of serological data, such as three-month intervals depending on the decay rate of antigen-specific antibodies. Given that household seroprevalence may be a robust proxy for past malaria exposure and is simultaneously associated with increased risk of asymptomatic infections and but reduced risk of clinical malaria (potentially due to partial immunity), the biological relationship between household serological status and the risk of clinical or parasitic infection could be further investigated through controlled observational cohort studies. These findings indicate that a number of new serological markers of malaria exposure could be useful for epidemiological surveillance in highly seasonal malaria transmission areas. There is potential for several of the antigenic targets explored to be used for population-wide screening, all of which have also been optimised for use on a multiplexed bead-based platform in research settings. Further translating this to a lateral flow device may offer opportunities for more widespread application if usecases can be well established.³² In light of the strong association between serological status and increased asymptomatic infection, serological platforms may have direct utility as a screening tool in

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

active or reactive case detection strategies, most of which have relied on clinical index cases presenting at health facilities and have shown variability in effectiveness.³³ Future work can also aim to develop standardised methods for characterising serological responses at the village or cluster level or as part of randomised trials, while optimal sampling timeframes and sentinel populations can be designed for use in routine surveillance. **Conclusions** As more countries move towards malaria elimination, including several in sub-Saharan Africa, sensitive diagnostics will be needed to further understand the dynamics between the parasite, host, and vector at very low levels of transmission. Integrating newly developed serology markers of recent exposure into existing field diagnostics will become more important in estimating the human reservoir and inform targeting of elimination approaches at very low levels of transmission. **List of abbreviations** aOR: Adjusted odds ratio CI: Confidence interval DBS: Dried blood spot EBA175: Erythrocyte binding antigen 175 Etramp5.Ag1: Early transcribed membrane protein 5 **GEE:** Generalised estimating equations GEXP18: Gametocyte export protein 18 (GEXP18) HSP40.Ag1: Heat shock protein 40 IgG: Immunoglobulin LLIN: Long-lasting insecticide treated net MDA: Mass drug administration (MDA) MFI: Median fluorescence intensity PCD: Passive case detection PCR: Polymerase chain reaction Pf, P.falciparum: Plasmodium falciparum PfAMA1: P.falciparum apical membrane antigen 1

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

PfMSP1₁₉: P.falciparum merozoite surface antigen 1 19-kDa carboxy-terminal region RDT: Rapid diagnostic test Rh2.2030: Reticulocyte binding protein homologue 2 URR: Upper River Region, The Gambia WCR: West Coast Region, The Gambia **Declaration of interests** Ethics approval and consent to participate This study was approved by the Gambia Government/MRC Joint Ethics Committee (SCC1318). Verbal consent was first obtained at village sensitisation meetings, followed by individual written informed consent for all participants. Parents/guardians provided written consent for children less than 17 years, and assent was obtained from children between 12 and 17 years. Availability of data and materials The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. **Competing interests** All authors declare no competing interests. **Funding** This study was funded by the UK Medical Research Council (UKMRC) through the LSHTM Doctoral Training Programme studentship received by LW. The funders had no role in the design of the study, collection, analysis, interpretation of data or writing of the manuscript. **Author contributions** LW designed and coordinated the study, supervised and performed serological lab work, analysed the data, and wrote the manuscript. JM and MA supervised field data collection and laboratory work. SC

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

and MB conducted the serological assays. KKAT and JB produced the antigens. KKAT and TH developed the serological assay. JM, MA, UD, IK, and CD advised on study design, interpretation of findings, and reviewed the manuscript. All authors read and approved the final manuscript. References 1. Okell, L. C. et al. Factors determining the occurrence of submicroscopic malaria infections and their relevance for control. Nat. Commun. 3, 1237 (2012). 2. Bousema, T., Okell, L., Felger, I. & Drakeley, C. Asymptomatic malaria infections: detectability, transmissibility and public health relevance. Nat. Rev. Microbiol. 12, 833-40 (2014). 3. Wu, L. et al. Comparison of diagnostics for the detection of asymptomatic Plasmodium falciparum infections to inform control and elimination strategies. Nature 528, S86-93 (2015). 4. Andrews, L. et al. Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. Am. J. Trop. Med. Hyg. 73, 191–8 (2005). 5. Rockett, R. J. et al. A real-time, quantitative PCR method using hydrolysis probes for the monitoring of Plasmodium falciparum load in experimentally infected human volunteers. Malar. J. 10, 48 (2011). 6. Okebe, J. et al. School-Based Countrywide Seroprevalence Survey Reveals Spatial Heterogeneity in Malaria Transmission in the Gambia. PLoS One 9, e110926 (2014). 7. van den Hoogen, L. L. et al. Serology describes a profile of declining malaria transmission in Farafenni, The Gambia. Malar. J. 14, 416 (2015). 8. Drakeley, C. J. et al. Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure. Proc. Natl. Acad. Sci. U. S. A. 102, 5108-13 (2005).9. Cook, J. et al. Serological markers suggest heterogeneity of effectiveness of malaria control

interventions on Bioko Island, equatorial Guinea. PLoS One 6, e25137 (2011).

421

422 10. Biggs, J. et al. Serology reveals heterogeneity of Plasmodium falciparum transmission in 423 northeastern South Africa: implications for malaria elimination. Malar. J. 16, 48 (2017). 424 Helb, D. A. et al. Novel serologic biomarkers provide accurate estimates of recent 11. 425 Plasmodium falciparum exposure for individuals and communities. Proc. Natl. Acad. Sci. U. S. 426 A. 112, E4438-47 (2015). 427 12. Kerkhof, K. et al. Serological markers to measure recent changes in malaria at population level in Cambodia. Malar. J. 15, 529 (2016). 428 429 13. Mwesigwa, J. et al. Residual malaria transmission dynamics varies across The Gambia despite 430 high coverage of control interventions. *PLoS One* **12**, e0187059 (2017). 431 14. Wu, L. et al. Optimisation and standardisation of a multiplex immunoassay of diverse 432 Plasmodium falciparum antigens to assess changes in malaria transmission using seroepidemiology. Wellcome Open Res. 4, 26 (2019). 433 434 15. Snounou, G. Genotyping of Plasmodium spp. Nested PCR. Methods Mol. Med. 72, 103-116 435 (2002).436 16. Helb, D. A. et al. Novel serologic biomarkers provide accurate estimates of recent 437 Plasmodium falciparum exposure for individuals and communities. Proc. Natl. Acad. Sci. U. S. A. 112, E4438-47 (2015). 438 439 17. Stewart, L. et al. Rapid assessment of malaria transmission using age-specific sero-conversion 440 rates. PLoS One 4, e6083 (2009). 441 18. Drakeley, C. J. et al. Estimating medium- and long-term trends in malaria transmission by 442 using serological markers of malaria exposure. Proc. Natl. Acad. Sci. U. S. A. 102, 5108-13 (2005).443 444 19. Bruce-Chwatt, L. J., Draper, C. C. & Konfortion, P. Seroepidemiological evidence of eradication

- of malaria from Mauritius. *Lancet (London, England)* **2**, 547–51 (1973).
- 446 20. Wong, J. et al. Serological markers for monitoring historical changes in malaria transmission
- intensity in a highly endemic region of Western Kenya, 1994-2009. *Malar. J.* **13**, 451 (2014).
- 448 21. Yman, V. et al. Antibody acquisition models: A new tool for serological surveillance of malaria
- transmission intensity. *Sci. Rep.* **6**, 19472 (2016).
- 450 22. Irion, A., Beck, H. P. & Smith, T. Assessment of positivity in immuno-assays with variability in
- 451 background measurements: a new approach applied to the antibody response to Plasmodium
- 452 falciparum MSP2. *J. Immunol. Methods* **259**, 111–8 (2002).
- 453 23. Vidarsson, G., Dekkers, G. & Rispens, T. IgG Subclasses and Allotypes: From Structure to
- 454 Effector Functions. *Front. Immunol.* **5**, (2014).
- 455 24. Dobaño, C. et al. Age-dependent IgG subclass responses to Plasmodium falciparum EBA-175
- 456 are differentially associated with incidence of malaria in Mozambican children. Clin. Vaccine
- 457 *Immunol.* **19**, 157–66 (2012).
- 458 25. Tongren, J. E. et al. Target antigen, age, and duration of antigen exposure independently
- 459 regulate immunoglobulin G subclass switching in malaria. *Infect. Immun.* **74**, 257–64 (2006).
- 460 26. Stanisic, D. I. et al. Acquisition of antibodies against Plasmodium falciparum merozoites and
- 461 malaria immunity in young children and the influence of age, force of infection, and
- 462 magnitude of response. *Infect. Immun.* **83**, 646–60 (2015).
- 463 27. Takala, S. L. & Plowe, C. V. Genetic diversity and malaria vaccine design, testing and efficacy:
- 464 preventing and overcoming 'vaccine resistant malaria'. *Parasite Immunol.* **31**, 560–573
- 465 (2009).
- 466 28. Scherf, A., Lopez-Rubio, J. J. & Riviere, L. Antigenic Variation in *Plasmodium falciparum*. *Annu.*
- 467 Rev. Microbiol. **62**, 445–470 (2008).
- 468 29. Neafsey, D. E. et al. Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria

Vaccine. N. Engl. J. Med. 373, 2025-2037 (2015). 30. Krishnarjuna, B. et al. Strain-transcending immune response generated by chimeras of the malaria vaccine candidate merozoite surface protein 2. Sci. Rep. 6, 20613 (2016). 31. Mosha, J. F. et al. Epidemiology of subpatent Plasmodium falciparum infection: implications for detection of hotspots with imperfect diagnostics. Malar. J. 12, 221 (2013). 32. Greenhouse, B. et al. Priority use cases for antibody-detecting assays of recent malaria exposure as tools to achieve and sustain malaria elimination. Gates Open Res. 3, 131 (2019). 33. Hsiang, M. S. et al. Active Case Finding for Malaria: A 3-Year National Evaluation of Optimal Approaches to Detect Infections and Hotspots Through Reactive Case Detection in the Lowtransmission Setting of Eswatini. Clin. Infect. Dis. (2019). doi:10.1093/cid/ciz403

Table 1. Serology sample size. Number of compounds and individuals by village and survey month.

	Compounds		Indivi	duals	
West Coast Region		July 2013	December 2013	April 2014	December 2014
Besse	69	401	388	-	-
N'Demban	24	136	138	-	-
Subtotal WCR	93	537	526	-	-
Upper River Region					
Njaiyal	28	382	181	298	286
Madina Samako	43	397	451	525	471
Subtotal URR	71	779	632	823	757
Total	164	1316	1158	823	757

Table 2. Study subject characteristics by region and survey month, n (%) out of total individual in monthly survey

West Coast Region	July 2013	December 2013	April 2014	December 2014
Gender			-	=
Male	240 (46.3)	227 (45.0)		
Female	278 (53.7)	277 (55.0)	-	-
Age category				
<5 years	112 (21.5)	104 (20.5)	-	-
5 -15 years	188 (36.1)	195 (38.5)	-	-
>15 years	221 (42.4)	208 (41.0)	-	-
LLIN use 24hr	519 (96.6)	492 (94.3)	-	=
Upper River Region	July 2013	December 2013	April 2014	December 2014
Gender				
Male	371 (47.9)	287 (45.7)	401 (49.0)	359 (47.5)
Female	404 (52.1)	341 (54.3)	417 (51.0)	396 (52.5)
Age category				
<5 years	164 (21.5)	144 (23.3)	186 (23.0)	175 (23.6)
5 -15 years	260 (34.1)	234 (37.8)	304 (37.6)	258 (34.9)
>15 years	339 (44.4)	241 (38.9)	318 (39.4)	307 (41.5)
LLIN use 24hr	278 (46.6)	245 (41.7)	301 (43.8)	283 (46.2)

Table 3. Regional sero-prevalence (ages 2-10 years) by antigen and all-age incidence rates for clinical malaria and *Pf* infection. Mean sero-prevalence (%) and incidence rates with 95%CI shown in parentheses.

	West Coast Re	egion (WCR)	Upper River Region (URR)		
	July 2013	December 2013	July 2013	December 2013	
Clinical incidence rate	0.08 (0.04 - 0.21)	0.14 (0.04 - 0.44)	0.13 (0.04 - 0.39)	0.21 (0.1 - 0.51)	
Pf infection incidence rate	0.23 (0.13 - 0.39)	0.67 (0.40 - 1.13)	0.56 (0.42 - 0.74)	2.87 (2.36 - 3.50)	
Sero-prevalence (ages 2-	10 years)				
Etramp5.Ag1	4.8% (1.9 - 7.8)	13.7% (8.9 - 18.5)	8.7% (5.4 - 12.1)	33.6% (27.6 - 39.6)	

GEXP18	12.6% (8.0 – 17.1)	12.7% (8.0 – 17.3)	25.1% (20.0 – 30.2)	36.1% (30.0 – 42.2)
HSP40.Ag1	6.3% (3.0 - 9.6)	6.1% (2.8 - 9.4)	8.4% (5.1 - 11.6)	24.1% (18.7 - 29.5)
Rh2.2030	1.4% (0.0 - 3.1)	1.0% (0.0 - 2.4)	9.8% (6.3 - 13.3)	25.3% (19.8 - 30.8)
EBA175	1.9% (0.1 - 3.8)	1.0% (0.0 - 2.4)	7.3% (4.2 - 10.3)	15.8% (11.2 - 20.4)
PfMSP1 ₁₉	3.4% (0.9 - 5.8)	8.1% (4.3 - 11.9)	5.1% (2.5 - 7.7)	22.0% (16.8 - 27.2)
PfAMA1	4.8% (1.9 - 7.8)	4.1% (1.3 - 6.8)	17.8% (13.3 - 22.3)	33.2% (27.2 - 39.1)

Table 4. Pearson's correlation coefficients between regional sero-prevalence (ages 2-10 years) and all-age incidence rates for clinical malaria and *Pf* infection. Correlation estimates are based on data from the West Coast Region (WCR) and Upper River Region (URR) in July and December 2013. Correlations excluding data from URR December 2013 are shown in brackets.

	Pearson's correlation coefficient					
Antigen	Sero-prevalence vs.	Sero-prevalence vs.				
	Clinical incidence rate	Pf infection incidence rate				
Etramp5.Ag1	0.98 [0.96]	0.98 [0.98]				
GEXP18	0.90 [0.69]	0.84 [0.63]				
HSP40.Ag1	0.95 [0.85]	0.99 [0.81]				
EBA175	0.87 [0.40]	0.91 [0.32]				
Rh2.2030	0.88 [0.39]	0.94 [0.31]				
PfMSP1 ₁₉	0.97 [0.96]	0.99 [0.98]				
<i>Pf</i> AMA1	0.87 [0.48]	0.89 [0.40]				

Table 5. Odds of clinical malaria and asymptomatic infection by individual serological status, unadjusted and adjusted for age group (<5 years, 5-15 years, and > 15 years) and LLIN use in the last 24 hours.

Odds of clinical malaria or asymptomatic infection amongst sero-positive individuals, by antigen						
	Unadjusted			Adjusted		
	OR	95%CI	p-value	aOR	95%CI	p-value
Etramp5.Ag1						
Clinical malaria	5.50	3.33 - 9.07	<0.001	4.56	2.94 - 7.06	< 0.001
Asymptomatic infection	3.24	2.67 – 3.94	<0.001	3.36	2.75 - 4.11	< 0.001
GEXP18						
Clinical malaria	2.40	1.38 - 4.18	0.002	1.40	0.85 - 2.31	0.182
Asymptomatic infection	2.99	2.43 - 3.68	<0.001	3.10	2.50 - 3.85	<0.001
HSP40.Ag1						
Clinical malaria	1.63	0.91 - 2.90	0.099	0.97	0.58 - 1.61	0.903
Asymptomatic infection	2.57	2.11 - 3.13	<0.001	2.66	2.14 - 3.31	< 0.001
Rh2.2030						
Clinical malaria	2.08	1.08 - 4.01	0.029	1.13	0.66 - 1.93	0.662
Asymptomatic infection	2.51	2.04 - 3.10	<0.001	3.10	2.44 - 3.94	<0.001
EBA175						
Clinical malaria	1.32	0.66 - 2.66	0.431	1.19	0.65 - 2.17	0.574

Asymptomatic infection	2.13	1.77 – 2.56	<0.001	2.68	2.09 - 3.94	<0.001
PfMSP1 ₁₉						
Clinical malaria	3.54	1.88 - 6.69	<0.001	3.82	2.41 - 6.04	<0.001
Asymptomatic infection	2.33	1.87 - 2.92	<0.001	2.50	1.93 - 3.24	<0.001
PfAMA1						
Clinical malaria	2.20	1.26 - 3.86	0.006	2.18	1.23 - 3.84	0.007
Asymptomatic infection	2.66	2.16 - 3.29	<0.001	3.83	2.95 - 4.98	<0.001

Table 6. Odds of clinical malaria and asymptomatic *Pf* **infection by compound serological status.** Estimates are weighted by compound size and shown as unadjusted odds ratios (OR) and adjusted odds ratios (aOR) for age group (<5 years, 5-15 years, and > 15 years).

Odds of clinical malaria or asymptomatic <i>Pf</i> infection for individuals residing in sero-positive compounds						
	Unadjusted				Adjusted	
	OR	95%CI	p-value	aOR	95%CI	p-value
Etramp5.Ag1						
Clinical malaria	0.18	0.03 - 1.00	0.050	0.17	0.03 - 0.84	0.030
Asymptomatic infection	2.91	1.66 - 5.12	<0.001	2.95	1.66 - 5.24	<0.001
GEXP18						
Clinical malaria	0.12	0.02 - 0.84	0.032	0.11	0.02 - 0.68	0.017
Asymptomatic infection	2.74	1.61 - 4.67	<0.001	2.71	1.58 - 4.63	< 0.001
HSP40.Ag1						
Clinical malaria	0.13	0.02 - 0.76	0.023	0.12	0.02 - 0.66	0.015
Asymptomatic infection	1.35	0.78 - 2.34	0.281	1.42	0.81 - 2.48	0.226
Rh2.2030						
Clinical malaria	0.07	0.01 - 0.46	0.006	0.06	0.01 - 0.33	0.001
Asymptomatic infection	1.73	0.97 - 3.06	0.062	1.96	1.12 - 3.44	0.019
EBA175						
Clinical malaria	0.07	0.01 - 0.58	0.014	0.07	0.01 - 0.54	0.011
Asymptomatic infection	1.04	0.53 - 2.05	0.915	1.06	0.53 - 2.13	0.875
PfMSP1 ₁₉						
Clinical malaria	0.15	0.03 - 0.83	0.030	0.11	0.03 - 0.48	0.003
Asymptomatic infection	1.92	1.17 - 3.14	0.010	2.00	1.21 - 3.29	0.007
PfAMA1						
Clinical malaria	0.06	0.01 - 0.56	0.014	0.05	0.01 - 0.47	0.009
Asymptomatic infection	2.01	1.03 - 3.91	0.040	2.04	1.03 - 4.03	0.041

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542


Figure legends Figure 1. Map of Malaria Transmission Dynamics Study with regions and study villages by PCR prevalence. Figure 2. Pearson's correlation between regional sero-prevalence (ages 2-10 years) and all-age incidence rates for clinical malaria and Pf infection. Correlations between sero-prevalence and incidence rates for clinical malaria (new clinical episodes divided by person-years at risk) in red and Pf infection (new PCR infections divided by person-years at risk) In blue were based on data from the West Coast Region (WCR) and the Upper River Region (URR) in July and December 2013. Correlations excluding data from URR December 2013 shown in brackets. Figure 3. Odds clinical malaria and asymptomatic infection by a) individual sero-positivity status b) residing in the same compound as a sero-positive individual. Analyses is adjusted for age group (<5 years, 5-15 years, and >15 years) and LLIN use in the last 24 hours and weighted by compound size. Figure 4. Odds of clinical malaria by compound sero-prevalence (a) and odds of asymptomatic infection by compound sero-prevalence (b). Analyses is adjusted for age group (<5 years, 5-15 years, and >15 years) and LLIN use in the last 24 hours and weighted by compound size. Figure 5. Household geolocation of Etramp5. Ag1 sero-positive, clinical malaria and Pf infections across four villages. Spatial distribution of infections shown for lower transmission (N'demban) and higher transmission (Besse) villages in the West Coast Region (WCR) and lower transmission (Njaiyal) and higher transmission (Madina Samako) villages in the Upper River Region (URR). Infections at the start of the wet season (June - July 2013) shown on the left and during the wet and transmission season (August – December 2013) on the right.

Additional files

Supplementary 1. Sero-prevalence amongst individuals aged 2 - 10 year and prevalence of seropositive compounds.

Supplementary 2. Odds of clinical malaria and asymptomatic infection for sero-positive individuals
and individuals residing in sero-positive compounds. Unadjusted and adjusted odds ratios for seven
malaria antigenic targets - Etramp5.Ag1, GEXP18, HSP40.Ag1, Rh2.2030, EBA175, PfMSP1₁₉, and
PfAMA1

Supplementary 3. Map of household geolocation of PfAMA1 sero-positive, clinical malaria and Pf
infections across four villages during dry and wet transmission seasons. Spatial distribution of
infections shown for lower transmission (N'demban) and higher transmission (Besse) villages in the
West Coast Region (WCR) and lower transmission (Njaiyal) and higher transmission (Madina Samako)
villages in the Upper River Region (URR). Infections at the start of the wet season (June – July 2013)
shown on the left and during the wet and transmission season (August – December 2013) on the right.



2.5 - 5.0


5.0 - 15.0

15.0 - 30.0

2.5 - 5.0


5.0 - 15.0

15.0 - 30.0




A. Odds of infection in sero-positive individuals

Reference: Sero-negative individuals




B. Odds of infection in sero-positive households

Reference: Individuals in sero-negative households




A. Clinical malaria in sero-positive households

Household sero-prevalence (hhSP) 1-50% and >50% Reference: Household sero-prevalence 0%



B. Asymptomatic infection in sero-positive households

Household sero-prevalence (hhSP) 1-50% and >50% Reference: Household sero-prevalence 0%



N'demban, WCR | Aug - Dec 2013 13.2085 13.2075 13.2075 13.2065 -16.3440 -16.3435 -16.3430 -16.3425 -16.3420 longitude

